Tong Ren Tang Technologies Co. Ltd.

1666

CNE100000585

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-05-13 am EDT			5-day change	1st Jan Change
5.85 ^HKD	+3.72%		+7.34%	-10.69%

Apr. 30	Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong	MT
Mar. 22	Tong Ren Tang Technologies Co. Ltd. Announces Final Ordinary Dividend for the Financial Year End 31 December 2023. Payable on August 9, 2024	CI

Tong Ren Tang Technologies Co. Ltd. Approves the Appointment of Feng Li as A Non-Executive Director

December 22, 2022 at 03:30 am EST

Tong Ren Tang Technologies Co. Ltd. at the EGM held on 22 December 2022, approved the appointment of Ms. Feng Li as a non-executive Director.

Latest news about Tong Ren Tang Technologies Co. Ltd.

Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong	Apr. 30	MT
Tong Ren Tang Technologies Co. Ltd. Announces Final Ordinary Dividend for the Financial Year End 31 December 2023. Payable on August 9, 2024	Mar. 22	CI
Tong Ren Tang Technologies Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
China Permits Clinical Trial of Tong Ren Teng's Anti-Blood Stasis Drug	Mar. 05	MT
Tong Ren Tang Technologies Co. Ltd. Receives Notice of Approval for Clinical Trial of Medicine	Mar. 05	CI
Tong Ren Tang Technologies' 2023 Profit to Slip Up to 7%	Jan. 30	MT
Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023	Jan. 29	CI
Tong Ren Tang Technologies Co. Ltd. Announces Board Changes	Jan. 22	CI
Beijing Tong Ren Tang Appoints Chairman	Dec. 13	MT
Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Gu Hai Ou as Executive Director, Chairman of the Board, Chairman of the Nomination Committee, Chairman of the Strategy and Planning Committee	Dec. 13	CI
Beijing Tong Ren Tang to Vote Dec. 27 on Renewal of Distributorship Contracts	Dec. 05	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes New Exclusive Distributorship Framework Agreements	Nov. 29	CI
Tong Ren Tang Logs 514 Million Yuan in Nine-Month Profit	23-10-26	MT
Tong Ren Tang Technologies' Profit Rises 16% in H1	23-08-25	MT
Tong Ren Tang Technologies Co. Ltd. Announces Board Changes	23-08-25	CI
Tong Ren Tang Technologies Co. Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Tong Ren Tang to Log Up to 17% Rise in H1 Profit	23-08-04	MT
Tong Ren Tang Technologies Co. Ltd. Provides Revenue Guidance for the Six Months Ended 30 June 2023	23-08-04	CI
Tong Ren Tang Technologies Co. Ltd. Announces Board Changes	23-06-15	CI
Tong Ren Tang Technologies Co. Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 14 August 2023	23-06-15	CI
Tong Ren Tang Technologies Co. Ltd. Announces Change in Joint Company Secretaries	23-04-27	CI
Tong Ren Tang Technologies Co. Ltd. Proposes Final Dividend for the Year Ended 31 December 2022	23-04-27	CI
Tong Ren Tang Technologies' Profit Jumps 15% in 2022	23-03-22	MT
Tong Ren Tang Technologies Co. Ltd. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 14 August 2023	23-03-22	CI
Tong Ren Tang Technologies Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI

Chart Tong Ren Tang Technologies Co. Ltd.

Duration

Period

Chart Tong Ren Tang Technologies Co. Ltd.

More charts

Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine products and health care products and the provision of traditional Chinese medicine diagnosis and treatment services. The Company is also engaged in the production, processing and acquisition of Chinese herbal medicines, drug sales, medical services and advertising. The Company mainly distributes its products in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tong Ren Tang Technologies Co. Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.215 CNY

Average target price

6.058 CNY

Spread / Average Target

+16.15%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
TONG REN TANG TECHNOLOGIES CO. LTD.	-10.69%	924M
DONG-E-E-JIAO CO.,LTD.	+43.17%	6.16B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.69%	4.46B
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.17%	3.27B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.95%	3.2B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.76%	2.6B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.20%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.85%	1.7B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.40%	1.66B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-9.91%	1.61B

Alternative Medicine